Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ancient herbal blend may get bowels moving after surgery

NCT ID NCT07765589

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This phase 2 trial tests whether TU-100, a traditional Japanese herbal medicine made from ginger, ginseng, and Japanese pepper, can help the gut recover faster after major abdominal or pelvic surgery. About 240 adults undergoing either bladder removal (radical cystectomy) or complex abdominal wall reconstruction will receive TU-100 or a placebo alongside standard enhanced recovery care. The main goal is to see if more patients achieve normal bowel function within three days after surgery, which could reduce the risk of postoperative ileus—a common complication where the gut temporarily stops working.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TU-100, a traditional Japanese herbal medicine made from processed ginger, ginseng, and Japanese pepper
What this could lead to
If effective, TU-100 could become a standard add-on to recovery protocols, helping patients regain bowel function faster after major surgery and potentially shortening hospital stays.
What could go wrong
This is a phase 2 trial, so results are preliminary. The herbal mixture may not outperform placebo, and its safety in surgical patients is still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants aged 18 years or older * American Society of Anesthesiologists (ASA) Physical Status Classification I-III * Scheduled to undergo elective open or minimally invasive Radical Cystectomy (RC) with continent or incontinent urinary diversion requiring bowel resection, or open or complex minimally invasive surgery for Complex Abdominal Wall Reconstruction (CAWR) with anticipated myofascial advancement flap and mesh placement for moderate or giant hernia defects * Body mass index (BMI) ≤40 kg/m² * Women of childbearing potential and men with partners of childbearing potential must agree to use highly effective contraception * Willing and able to comply with study procedures and able to voluntarily provide informed consent Exclusion Criteria: * Not scheduled for a Radical Cystectomy (RC) or Complex Abdominal Wall Reconstruction (CAWR) procedure meeting the inclusion criteria * Known gastric or bowel obstruction * Have had or have planned gastrectomy, gastric bypass, colostomy, or ileostomy * Significant gastrointestinal motility disorders * Pregnancy or breastfeeding * Clinically significant hepatic, renal, cardiovascular, or other uncontrolled medical conditions * Immunocompromised state or recent immunosuppressive therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Delay in gi recovery/postoperative ileus (POI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.